KOD Kodiak Sciences Inc. Stock Quote

KOD [NASD]

Index	-	P/E	-	EPS (ttm)	-3.83	Insider Own	0.40%	Shs Outstand	51.57M	Perf Week	-0.70%
Market Cap	5.63B	Forward P/E	-	EPS next Y	-6.01	Insider Trans	172.37%	Shs Float	45.57M	Perf Month	11.35%
Income	-189.00M	PEG	-	EPS next Q	-1.16	Inst Own	89.50%	Short Float	7.56%	Perf Quarter	27.35%
Sales	-	P/S	-	EPS this Y	-132.50%	Inst Trans	1.21%	Short Ratio	15.45	Perf Half Y	-8.81%
Book/sh	15.11	P/B	7.41	EPS next Y	-32.10%	ROA	-21.10%	Target Price	121.55	Perf Year	14.49%
Cash/sh	17.51	P/C	6.39	EPS next 5Y	12.40%	ROE	-27.60%	52W Range	73.19 - 171.21	Perf YTD	-23.83%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-34.64%	Beta	-
Dividend %	-	Quick Ratio	21.60	Sales past 5Y	-	Gross Margin	-	52W Low	52.89%	ATR	4.36
Employees	76	Current Ratio	21.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	61.43	Volatility	4.11% 3.93%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-87.30%	Profit Margin	-	Rel Volume	0.51	Prev Close	111.63
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 09 AMC	Payout	-	Avg Volume	223.01K	Price	111.90
Recom	2.50	SMA20	5.18%	SMA50	11.38%	SMA200	4.75%	Volume	114,510	Change	0.24%

May-11-21

Upgrade

ROTH Capital

Neutral → Buy

$155 → $149

Mar-12-21

Initiated

Evercore ISI

Outperform

Mar-01-21

Downgrade

Barclays

Equal Weight → Underweight

$52 → $90

Feb-17-21

Downgrade

ROTH Capital

Buy → Neutral

$133 → $155

Jan-25-21

Downgrade

BMO Capital Markets

Outperform → Market Perform

$145 → $148

Dec-17-20

Initiated

Berenberg

Buy

$156

Dec-16-20

Initiated

UBS

Buy

$170

Dec-11-20

Initiated

Citigroup

Neutral

$134

Nov-30-20

Downgrade

JP Morgan

Overweight → Neutral

$74 → $125

Nov-16-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$80 → $125

Nov-13-20

Downgrade

Goldman

Buy → Neutral

$83 → $105

Mar-31-20

Initiated

BMO Capital Markets

Outperform

$74

Mar-03-20

Initiated

Goldman

Buy

$80

Feb-18-20

Downgrade

Barclays

Overweight → Equal Weight

$69

Feb-06-20

Initiated

SunTrust

Buy

Jan-08-20

Initiated

ROTH Capital

Buy

$115

Jan-03-20

Initiated

Jefferies

Buy

$100

Dec-24-19

Initiated

JP Morgan

Overweight

$82

Oct-15-19

Reiterated

Chardan Capital Markets

Buy

$22.50 → $35

Feb-20-19

Initiated

Chardan Capital Markets

Buy

$22.50

Oct-11-21 09:36AM	We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely Simply Wall St.
Sep-10-21 04:47PM	Notable Kodiak Sciences Insider Makes $5.37 Million Buy Benzinga
07:32AM	3 Stocks Insiders Are Buying Benzinga
Sep-08-21 11:30AM	Kodiak Sciences Inc. (KOD) Up 15.7% Since Last Earnings Report: Can It Continue? Zacks
Sep-01-21 05:45AM	Kodiak Sciences Announces New Long-Term Performance Incentive Plan PR Newswire
Aug-31-21 05:02AM	Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference PR Newswire
Aug-20-21 10:14AM	4 Stocks Insiders Are Buying Benzinga
Aug-10-21 10:21AM	Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus Zacks
Aug-09-21 04:01PM	Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights PR Newswire
Jul-29-21 07:00AM	Is This Mid-Cap Biotech Stock a Buy Now? Motley Fool
Jul-27-21 08:05PM	Were Hedge Funds Right About Selling Kodiak Sciences Inc (KOD)? Insider Monkey
Jul-23-21 07:33AM	Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet Benzinga
Jun-09-21 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report? Zacks
May-20-21 07:00PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
May-19-21 09:58AM	Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Kodiak Sciences Inc. (NASDAQ: KOD) Investors GlobeNewswire
May-18-21 02:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Kodiak Sciences Inc. - KOD PR Newswire
May-11-21 11:04AM	Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus Zacks -7.59%
May-10-21 12:30PM	Why Kodiak Sciences Stock Is Tumbling Today Motley Fool -13.00%
05:30AM	Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights PR Newswire
May-06-21 12:19PM	Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat? Zacks -5.04%
May-04-21 12:00PM	What Makes Kodiak Sciences Inc. (KOD) a New Buy Stock Zacks -5.34%
Apr-21-21 06:59PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
Mar-02-21 04:12PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire -7.14%
10:13AM	Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus Zacks
Mar-01-21 05:30AM	Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights PR Newswire
Feb-16-21 06:07AM	Kodiak Sciences' KSI-301 Shows Durable Benefit In Retinal Disease Settings Benzinga -7.29%
Feb-13-21 08:28AM	Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting PR Newswire
Feb-09-21 04:50AM	How One Woman Turned a $40 Million Kuaishou Bet Into $12 Billion Bloomberg
Feb-02-21 07:14AM	Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition PR Newswire +7.01%
Jan-05-21 08:02AM	Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference PR Newswire
Dec-18-20 01:41AM	Is KOD A Good Stock To Buy Now? Insider Monkey
Nov-27-20 03:02PM	Kodiak Sciences, Playa Hotel See Activist Action Barrons.com
Nov-20-20 04:03PM	Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Nov-17-20 09:02PM	Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock PR Newswire
01:16PM	Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study Zacks
Nov-16-20 04:01PM	Kodiak Sciences Announces Proposed Offering of Common Stock PR Newswire
06:53AM	Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration PR Newswire
Nov-12-20 04:12PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
Nov-11-20 11:27PM	Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting PR Newswire
Nov-10-20 11:44AM	Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus Zacks
Nov-09-20 05:30AM	Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights PR Newswire
Oct-26-20 07:53AM	2 Top Healthcare Stocks That Jumped Last Week Motley Fool
Oct-12-20 04:56PM	Hedge Funds Are Getting Bullish On Kodiak Sciences Inc (KOD) Insider Monkey
Oct-05-20 09:02AM	Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion PR Newswire
Sep-02-20 04:08PM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
Aug-10-20 05:30AM	Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights PR Newswire
Jul-31-20 06:00AM	How Bill Gates would treat COVID-19 if he were President of the United States Yahoo Finance Video
Jul-16-20 04:38PM	Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress PR Newswire -6.66%
Jul-10-20 04:00PM	Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting PR Newswire
Jul-07-20 08:38AM	Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar PR Newswire
Jul-05-20 03:30PM	Hedge Funds Keep Buying Kodiak Sciences Inc (KOD) Insider Monkey
Jun-12-20 10:20PM	Why Kodiak Sciences (KOD) Stock Might be a Great Pick Zacks
Jun-05-20 12:00PM	Kodiak Sciences Inc. (KOD) Upgraded to Buy: What Does It Mean for the Stock? Zacks -7.40%
May-29-20 01:38PM	Top Small Cap Stocks for June 2020 Investopedia
May-28-20 08:22AM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire
May-26-20 11:02AM	Kodiak Sciences' Shares March Higher, Can It Continue? Zacks
May-13-20 07:01AM	Kodiak Sciences Inc. (KOD) Q1 2020 Earnings Call Transcript Motley Fool
May-11-20 04:13PM	Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference PR Newswire
05:30AM	Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights PR Newswire
May-08-20 04:30PM	Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020 PR Newswire
Apr-07-20 11:35AM	Hedge Funds Have Never Been This Bullish On Kodiak Sciences Inc (KOD) Insider Monkey -8.25%
Apr-02-20 04:08PM	Kodiak Sciences Appoints Charles Bancroft to Board of Directors PR Newswire
Mar-24-20 04:23PM	Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch
08:51AM	"Kodiak" and "Kodiak Sciences" Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use PR Newswire
Mar-23-20 01:37PM	Laurent Condon Triumphs Again, Wins My 3-Stock Derby GuruFocus.com
Mar-18-20 02:29PM	Top Biotech Stocks for Q2 2020 Investopedia -8.13%
Mar-16-20 05:30AM	Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights PR Newswire -24.16%
Mar-03-20 12:08PM	3 Reasons Goldman Sachs Is Bullish On Kodiak Sciences Benzinga
Feb-27-20 06:00AM	Kodiak Sciences to Present at Upcoming Conferences PR Newswire -7.69%
Feb-21-20 03:14PM	3 micro-cap names that may capture unicorn-like growth: Analyst Yahoo Finance
Feb-08-20 03:30PM	Kodiak Sciences Announces Additional Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation, and Degeneration 2020 Meeting PR Newswire
Jan-14-20 03:56PM	These 3 Momentum Stocks Have Room for Further Upside, Says Jefferies TipRanks
Jan-08-20 06:00AM	Kodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-27-19 02:19PM	Biotech Rally Sends Nasdaq to 9000: ETFs in Focus Zacks
Dec-26-19 07:55AM	The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares Benzinga
Dec-25-19 11:30AM	Is Kodiak Sciences (KOD) Stock Outpacing Its Medical Peers This Year? Zacks
Dec-24-19 12:00PM	Kodiak Sciences Inc. (KOD) is a Great Momentum Stock: Should You Buy? Zacks +15.96%
Dec-22-19 01:21PM	Did Hedge Funds Drop The Ball On Kodiak Sciences Inc (KOD) ? Insider Monkey
Dec-20-19 07:30AM	Will Kodiak Sciences Continue to Surge Higher? Zacks
Dec-19-19 04:01PM	Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors PR Newswire
12:20PM	Surging Earnings Estimates Signal Upside for Kodiak Sciences Inc. (KOD) Stock Zacks
Dec-14-19 07:30AM	Surging Biotech Stocks Kodiak Sciences, Immunomedics See Largest Holders Buy More Barrons.com
Dec-06-19 04:15PM	Kodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Dec-03-19 09:07PM	Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock PR Newswire
08:41AM	Benzinga Pro's Top 6 Stocks To Watch For Tues., Dec. 3, 2019: CARA, VRAY, LE, KOD, FXI, ROKU Benzinga
07:59AM	The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
Dec-02-19 05:00PM	Kodiak Sciences Announces Proposed Offering of Common Stock PR Newswire +72.47%
09:51AM	Longtime biotech investor injects $250M into Palo Alto company a year after IPO American City Business Journals
07:00AM	Kodiak Sciences to Present at the Evercore ISI HealthCONx Conference PR Newswire
06:00AM	Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors PR Newswire
Nov-27-19 12:15PM	5 Stocks That Pushed Russell 2000 ETF Higher Zacks
Nov-12-19 07:20AM	The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga -6.10%
05:30AM	Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights PR Newswire
Nov-08-19 07:00AM	Kodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019 PR Newswire
Oct-11-19 07:58PM	Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day PR Newswire +7.63%
06:00AM	Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301 PR Newswire
Oct-10-19 07:39PM	Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration PR Newswire +9.03%
Oct-07-19 06:00AM	Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting PR Newswire
Oct-04-19 02:27PM	Disappointed by WeWork? Check Out These IPO Stocks. InvestorPlace
Sep-15-19 06:08AM	Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting PR Newswire

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EHRLICH JASON	See Remarks	Oct 20	Option Exercise	10.29	6,950	71,516	58,491	Oct 22 04:52 PM
EHRLICH JASON	See Remarks	Oct 20	Sale	111.77	6,950	776,824	51,541	Oct 22 04:52 PM
BAKER BROS. ADVISORS LP	Director	Sep 30	Buy	95.83	86,932	8,330,572	13,526,726	Oct 01 04:58 PM
BAKER BROS. ADVISORS LP	Director	Sep 29	Option Exercise	0.01	149,999	1,500	13,439,808	Oct 01 04:58 PM
EHRLICH JASON	See Remarks	Sep 20	Option Exercise	10.29	6,950	71,516	58,491	Sep 22 05:02 PM
EHRLICH JASON	See Remarks	Sep 20	Sale	99.88	6,950	694,164	51,541	Sep 22 05:02 PM
BAKER BROS. ADVISORS LP	Director	Sep 16	Buy	94.59	1,153	109,064	13,300,993	Sep 17 06:05 PM
BAKER BROS. ADVISORS LP	Director	Sep 15	Buy	94.39	30,685	2,896,216	13,299,840	Sep 17 06:05 PM
BAKER BROS. ADVISORS LP	Director	Sep 07	Buy	93.31	57,501	5,365,227	13,269,155	Sep 09 06:43 PM
EHRLICH JASON	See Remarks	Aug 20	Option Exercise	10.29	5,258	54,105	58,491	Aug 24 04:59 PM
EHRLICH JASON	See Remarks	Aug 20	Sale	91.44	6,950	635,534	51,541	Aug 24 04:59 PM
BAKER BROS. ADVISORS LP	Director	Aug 19	Buy	87.56	83,648	7,323,898	13,211,654	Aug 19 05:12 PM
BAKER BROS. ADVISORS LP	Director	Aug 18	Buy	87.89	22,584	1,984,806	13,128,006	Aug 19 05:12 PM
BAKER BROS. ADVISORS LP	Director	Aug 17	Buy	85.90	8,164	701,254	13,105,422	Aug 19 05:12 PM
BAKER BROS. ADVISORS LP	Director	Aug 13	Buy	88.66	38,264	3,392,579	13,097,258	Aug 13 07:14 PM
BAKER BROS. ADVISORS LP	Director	Aug 12	Buy	87.29	10,986	958,954	13,058,994	Aug 13 07:14 PM
BAKER BROS. ADVISORS LP	Director	Aug 11	Buy	86.11	53,523	4,609,090	13,048,008	Aug 13 07:14 PM
EHRLICH JASON	See Remarks	Jul 20	Sale	86.28	6,950	599,624	53,233	Jul 22 04:37 PM
EHRLICH JASON	See Remarks	Jun 21	Sale	84.90	6,950	590,085	60,183	Jun 23 05:38 PM
EHRLICH JASON	See Remarks	Jun 15	Sale	84.75	1,147	97,208	64,968	Jun 15 07:06 PM
BORGESON JOHN A.	See Remarks	Jun 15	Sale	84.75	1,037	87,886	167,990	Jun 15 07:04 PM
EHRLICH JASON	See Remarks	Jun 15	Sale	80.90	1,454	117,624	67,133	Jun 17 09:26 PM
BORGESON JOHN A.	See Remarks	Jun 15	Sale	80.90	1,290	104,361	170,319	Jun 17 09:24 PM
EHRLICH JASON	See Remarks	May 20	Sale	81.14	6,950	563,924	63,161	May 24 04:59 PM
EHRLICH JASON	See Remarks	May 12	Option Exercise	10.21	7,268	74,240	70,111	May 14 05:22 PM
EHRLICH JASON	See Remarks	Apr 20	Option Exercise	10.29	6,950	71,516	69,793	Apr 22 04:59 PM
EHRLICH JASON	See Remarks	Apr 20	Sale	111.26	6,950	773,249	62,843	Apr 22 04:59 PM
EHRLICH JASON	See Remarks	Mar 22	Option Exercise	10.29	6,950	71,516	69,793	Mar 24 05:07 PM
EHRLICH JASON	See Remarks	Mar 22	Sale	131.50	6,950	913,894	62,843	Mar 24 05:07 PM
BORGESON JOHN A.	See Remarks	Mar 10	Sale	130.08	5,000	650,415	165,899	Mar 12 05:02 PM
EHRLICH JASON	See Remarks	Mar 03	Option Exercise	10.29	12,500	128,625	62,843	Mar 05 05:44 PM
EHRLICH JASON	See Remarks	Feb 22	Option Exercise	10.29	6,950	71,516	57,293	Feb 24 04:44 PM
EHRLICH JASON	See Remarks	Feb 22	Sale	125.81	6,950	874,367	50,343	Feb 24 04:44 PM
EHRLICH JASON	See Remarks	Jan 20	Option Exercise	10.29	26,950	277,316	77,293	Jan 22 05:22 PM
EHRLICH JASON	See Remarks	Jan 20	Sale	162.77	26,950	4,386,776	50,343	Jan 22 05:22 PM
EHRLICH JASON	See Remarks	Dec 23	Option Exercise	10.29	7,500	77,175	50,343	Dec 23 05:40 PM
EHRLICH JASON	See Remarks	Dec 21	Option Exercise	10.29	6,950	71,516	49,793	Dec 23 05:40 PM
EHRLICH JASON	See Remarks	Dec 21	Sale	144.55	6,950	1,004,610	42,843	Dec 23 05:40 PM
EHRLICH JASON	See Remarks	Nov 20	Option Exercise	10.29	6,950	71,516	49,793	Nov 24 06:04 PM
EHRLICH JASON	See Remarks	Nov 20	Sale	138.79	6,950	964,601	42,843	Nov 24 06:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience